ClouDr Group (HKSE:09955) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:09955 ClouDr Group Ltd HKSE:09955
48 GF Score
Price HK$0.51
GF Value HK$0.81
Valuation Possible Value Trap
! 9 Warning Signs
View Full Analysis

What is ClouDr Group FFO?

FFO (Funds from operations) only applies to REITs.

HKSE:09955
48GF Score
ClouDr Group Ltd HKSE:09955
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is ClouDr Group (HKSE:09955) Overvalued in 2026?

Based on GuruFocus' analysis, ClouDr Group stock appears to be undervalued. The current stock price of HK$0.51 is trading 37% below its estimated GF Value™ of HK$0.81. GuruFocus considers ClouDr Group to be Possible Value Trap.

Key valuation signals for HKSE:09955:

  • FFO:
  • GF Value™: HK$0.81 vs. price of HK$0.51 (37% below fair value)
  • GF Score™: 48/100 with 9 warning signs

No single metric tells the full story. See the HKSE:09955 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ClouDr Group Business Description

Address No. 998 Wenyi West Road (Haichuang Yuan), Wuchang Street, Rooms 501, 5th Floor, Building 12, Yuhang District, Zhejiang Province, Hangzhou, CHN
ClouDr Group Ltd provides supplies and SaaS to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions to patients, all centered around chronic condition management. The company's in-hospital solution consists of sales of medical devices, consumables, and pharmaceuticals, hospital SaaS, and digital marketing services to pharmaceutical companies, and the out-of-hospital solution connects doctors and patients, and provides high-quality and trustworthy medical services through the AI vertical model ClouD GPT. The company generates revenues from sales of hospital and pharmacy supplies and individual chronic condition management products.
48GF Score

Get the complete analysis for HKSE:09955

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.51
Price
HK$0.81
GF Value